Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets
| Autor: | Dong-Sheng Huang, Yuan Ma, Hai Zou, Lin-Yan Qian, Qiang Xu, Ya-Hui Ding, Li-Hong Wang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Disease Review 030204 cardiovascular system & hematology Bioinformatics Pathogenesis 03 medical and health sciences 0302 clinical medicine Insulin resistance Fibrosis Internal medicine insulin resistance renin angiotensin aldosterone system Renin–angiotensin system medicine atrial fibrillation Adiponectin adiponectin business.industry Fatty liver nutritional and metabolic diseases non-alcoholic fatty liver disease Atrial fibrillation medicine.disease digestive system diseases Endocrinology Oncology 030211 gastroenterology & hepatology business |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | Non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) are common chronic non-infectious diseases with rising incidences. NAFLD is an independent risk factor for the onset of AF, after adjusting potentially related factors. The pathogenesis of these diseases share several mechanisms including reduced adiponectin level, insulin resistance, and renin angiotensin aldosterone system (RAAS) activation, in addition to activation of common disease pathways that promote inflammation, oxidative stress, and fibrosis. Furthermore, statins and RAAS blockers exert therapeutic effects concurrently on NAFLD and AF. The common pathogenesis of NAFLD and AF may serve as a potential therapeutic target in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|